ILMN — ILLUMINA, INC.

Nasdaq · Unknown · Unknown · CIK 1110803 ·
Last close
$145.23
Market Cap
$21.97B
52W High
$150.20
52W Low
$115.31
ADV30
1,586,782
Next earnings
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 1,091,000,000 721,000,000 209,000,000 134,000,000 6,559,000,000 1,089,000,000 3,883,000,000
Dec 2025 1,159,000,000 759,000,000 211,000,000 334,000,000 6,644,000,000 1,418,000,000 3,921,000,000
Sep 2025 1,084,000,000 733,000,000 227,000,000 150,000,000 6,177,000,000 1,050,000,000 3,796,000,000
Jun 2025 1,059,000,000 695,000,000 214,000,000 235,000,000 6,087,000,000 934,000,000 3,829,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,128,000,000
Investing CF
$-358,000,000
Financing CF
$-800,000,000
CapEx
$-154,000,000
Dividends Paid
Buybacks
$-784,000,000
EPS Diluted TTM
$5.50
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-258,000,000
Inventory
$611,000,000
Receivables
$738,000,000
ST Investments
$66,000,000
EBIT TTM
$1,160,000,000
Pretax Income TTM
$1,060,000,000
Interest Exp TTM
$100,000,000
Analysts
18

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,392,999,936
EBITDA
$1,155,000,064
Free Cash Flow
$845,625,024
Enterprise Value
$23,238,232,064
Total Cash
$1,155,000,064
Total Debt
$2,544,000,000
Shares Out
151,300,000
Trailing EPS
$5.50
Book Value
$17.61
ROE
33.8%
ROA
8.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 4,343,000,000 817,000,000 850,000,000 6,644,000,000 3,921,000,000 1,079,000,000
Dec 2024 4,372,000,000 600,000,000 -1,223,000,000 6,303,000,000 3,930,000,000 837,000,000
Dec 2023 4,504,000,000 -222,000,000 -1,161,000,000 10,111,000,000 4,366,000,000 478,000,000
Dec 2022 4,584,000,000 354,000,000 -4,404,000,000 12,252,000,000 5,653,000,000 392,000,000

TTM Snapshot

Revenues TTM
$4,422,000,000
NetIncome TTM
$-3,548,000,000
OpCashFlow TTM
$0
Assets (Latest)
$6,303,000,000
Forward EPS
$5.93

News headlines (Yahoo Finance, 1h cache)

Illumina (ILMN) Valuation Check After Strong Recent Share Price Momentum
2026-05-23 10:22 · Yahoo
David P. King elected to Illumina's Board of Directors
2026-05-21 20:15 · Yahoo
[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate,
2026-05-21 17:30 · Yahoo
3 Reasons to Sell ILMN and 1 Stock to Buy Instead
2026-05-20 12:52 · Yahoo
Is This the Right Time to Retain ILMN Stock in Your Portfolio?
2026-05-20 12:39 · Yahoo
Earnings Beat, Buyback, China Signals Might Change The Case For Investing In Illumina (ILMN)
2026-05-19 22:14 · Yahoo
Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact
2026-05-19 20:30 · Yahoo
This Beaten-Down Growth Stock Could Soar 30%, According to Wall Street
2026-05-18 21:00 · Yahoo
1 Surging Stock on Our Buy List and 2 Facing Challenges
2026-05-18 08:12 · Yahoo
Illumina's Mid-Teens Clinical Growth Appears Sustainable Over Next 1 to 2 Years, RBC Says
2026-05-15 16:17 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.